Literature DB >> 16790945

Endocrine cancer in Iran: based on cancer registry system.

V Haghpanah1, B Soliemanpour, R Heshmat, A R Mosavi-Jarrahi, S M Tavangar, R Malekzadeh, B Larijani.   

Abstract

BACKGROUND: A population-based registry of endocrine cancer cases in four Iranian provinces, was performed for the years 1996-2000.
MATERIALS AND METHODS: Patients in each province were grouped according to age, gender and tumor specifics (site, morphology, behavior) and the data was coded according to the international classification of diseases for oncology. STATISTICAL ANALYSIS USED: Person-years of population at risk were calculated and the results were presented as incidence rates by sex, age, age specific rates and age standard rate (ASR) per 100,000 person-years, using direct method of standardization to the world population.
RESULTS: A total of 319 cases of primary endocrine cancer were found and registered, including 313 cases of thyroid carcinoma and 6 cases of adrenal cancer. The thyroid carcinoma group cases consisted of papillary (82.7%), follicular (8.6%), medullary (7.0%) and anaplastic (1.6%) carcinomas. The ASR for thyroid carcinoma was 1.289 (0.627 for men, 1.59 for women), with the highest incidence rate in Kerman (ASR 1.643) and the lowest incidence rate in Golestan (ASR 0.735). For the 6 cases of adrenal cancer, 4 were neuroblastoma and 2 were pheochromocytoma.
CONCLUSIONS: Iran was considered as an endemic, iodine-deficient area, until fairly recently. Iodinization of salt has been started about 12 years ago, in the nation. Considering the effect of improvement in the iodine intake in previously deficient communities, which is associated with an increase in the incidence of papillary carcinoma compared to other histologic types, the frequency and distribution of histologic types of thyroid carcinoma was closer to what can be seen in iodine-rich areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790945     DOI: 10.4103/0019-509x.25889

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  22 in total

1.  Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?

Authors:  S Adeleh Razavi; Mohammad Hossein Modarressi; Parichehr Yaghmaei; S Mohammad Tavangar; Mehdi Hedayati
Journal:  Endocrine       Date:  2017-07-28       Impact factor: 3.633

Review 2.  The Prevalence of Thyroid Cancer in Iran: a Systematic Review and Meta-analysis.

Authors:  Nader Salari; Mohsen Kazeminia; Masoud Mohammadi
Journal:  Indian J Surg Oncol       Date:  2021-11-12

3.  Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma.

Authors:  Haitham Alfalah; Isaac Cranshaw; Thomas Jany; Laurent Arnalsteen; Emmanuelle Leteurtre; Catherine Cardot; François Pattou; Bruno Carnaille
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 4.  Epidemiologic pattern of cancers in Iran; current knowledge and future perspective.

Authors:  Esmaeil Mohammadi; Arya Aminorroaya; Nima Fattahi; Sina Azadnajafabad; Nazila Rezaei; Yosef Farzi; Shohreh Naderimagham; Negar Rezaei; Bagher Larijani; Farshad Farzadfar
Journal:  J Diabetes Metab Disord       Date:  2020-10-20

5.  Investigating the demographic characteristics and pathological manifestations of thyroid Cancer during the last two decades (1997-2017) in patients referred to Baqiyatallah hospital, Tehran, Iran.

Authors:  Majid Ramezani; Masoumeh Saeidi; Ali Zarei; Mahmoud Hasani
Journal:  J Diabetes Metab Disord       Date:  2020-08-23

6.  Recent Trends and Geographical Distribution of Thyroid Cancer in Iran from 2004 to 2009.

Authors:  Ali Safavi; Rozita Jafari; Samira Chaibakhsh; Rashid Ramezani-Daryasar; Mansour Rezaei; Amir Ali Safavi
Journal:  Iran J Cancer Prev       Date:  2014

7.  Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Abbasali Keshtkar; Mahsa Mohammadamoli; Ladan Teimoori-Toolabi; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

8.  Genetic and Epigenetic of Medullary Thyroid Cancer

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran Biomed J       Date:  2017-11-11

9.  Circulating Tumor BRAF Mutation and Personalized Thyroidzzm321990Cancer Treatment

Authors:  Fatemeh Khatami; Bagher Larijani; Seyed Mohammad Tavangar
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

Review 10.  Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.